Navigation Links
US Brachytherapy Market to Reach $1.6 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
Date:6/22/2009

GIA announces the release of a comprehensive global report on Brachytherapy market. Brachytherapy is emerging as an effective treatment option for cancer patients with the market projected to reach $1.6 billion by 2015. Primary growth drivers include rising prevalence of cancer, growing medical awareness, improving success rate of brachytherapy, and advent of advanced radiation technologies.

San Jose, CA (PRWEB) June 22, 2009 -- Rising proportion of cancer population in both developed and developing countries is expected to enhance the demand for brachytherapy for cancer treatment. In particular, brachytherapy has emerged as the effective treatment option for prostate cancer patients, who have failed to achieve desirable results through surgery or external radiation therapy. With long-term clinical data offering support for the effectiveness of brachytherapy in reducing size of the tumor, the therapy is expected to gain strength. With indications for brachytherapy ranging from prostate cancer, head and neck cancer, cervical cancer, and breast cancer to coronary applications, the rapidly aging world population represents a strong demographic growth driver.

The United States represents the largest as well as the fastest growing market for brachytherapy. In the United States, increasing incidence of cancer cases and related mortality rates are contributing to the increasing demand for brachytherapy, as stated in the new report. Rising awareness about risks of surgery and external radiation therapy are fostering advancements in technologies and products for less invasive treatment for cancer. Growing uptake of brachytherapy is also attributed to the increasing success rates of prostate brachytherapy, breast brachytherapy, and head and neck brachytherapy procedures. Driven by the minimally invasive nature of the procedure, Implantable Prostate Seed Therapy is expected to continue posting healthy gains in the market.

Further, balloon brachytherapy for breast cancer treatment is expected to gain rapid acceptance among patients and physicians alike. Post-Operative Brachytherapy market is the fastest growing segment. Growing concerns over rising cancer levels, increasing awareness about adverse effects of EBRT, constant improvements in technologies and devices, and wider acceptance of brachytherapy are expected to boost prospects in the European post-surgical brachytherapy market.

Competition in the brachytherapy market is intensifying, particularly in the implantable prostate seed segment with Oncura Corp., CR Bard, NAS Medical, Theragenics Corporation, and Xoft, competing for a share of the lucrative market. Major players profiled in the report include Best Medical International Inc, BrachySciences Inc, C. R. Bard Inc, Core Oncology, Cytogen Corporation, Cytyc Corporation, Eckert & Ziegler Strahlen- und Medizintechnik AG, International Brachytherapy SA, Oncura, Inc., Theragenics Corporation Sirtex Medical Ltd, Varian Medical Systems Inc, Xoft Inc, among several others.

"Brachytherapy: A US and European Market Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of prevailing market issues and trends, competitive scenario, and recent industry activity in the brachytherapy market. Analytics for the period 2005-2015 provide a comprehensive understanding of markets including the United States and Europe. The markets are analyzed in terms of Number of Procedures (Thousands) and Annual Revenues (US$ Million) for the segments - Implantable Prostate Seed and Post-Surgical Brachytherapy.

For more details about this comprehensive market research report, please visit - http://www.strategyr.com/Brachytherapy_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press (at) StrategyR.com
Web Site http://www.StrategyR.com/

# # #

Read the full story at http://www.prweb.com/releases/brachytherapy/endovascular/prweb2483664.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Varian Medical Systems to Unveil RapidArc(TM) Volumetric Arc Therapy and Other Products Designed to Speed Delivery of Precision Radiotherapy and Brachytherapy
2. FDA Clears New Skin and Surface Treatment Applicator for Use With Xofts Axxent(R) Electronic Brachytherapy (eBx) System
3. R&D Magazine Selects Xoft Axxent(R) Electronic Brachytherapy System as Editors Choice Innovation Award Winner
4. High dosage brachytherapy obtains excellent results in head and neck tumors
5. Prostate Cancer Patients in US and Europe Receive Treatments Using Enhanced Seed Prostate Brachytherapy Software
6. Xoft Receives Health Canada Regulatory Approval for the Axxent(R) Electronic Brachytherapy System
7. Varian Medical Systems Introduces Fast and Precise Brachytherapy Planning System at GEC-ESTRO in Portugal
8. New Fast and Precise Treatment Planning System Among Varian Medical Systems Highlights at American Brachytherapy Society 2009 Meeting
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
US Brachytherapy Market to Reach $1.6 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 
(Date:4/25/2017)... ... April 25, 2017 , ... ... analytics to its patient care management module. Using this new feature, sleep physicians ... has been initiated on continuous positive airway pressure (CPAP), oral, or other forms ...
(Date:4/25/2017)... ... ... There is no better place in South Florida to undergo two common heart ... of Consumer Reports focused on heart health. , The magazine gave Memorial ... bypass and aortic valve replacement procedures. , Consumer Reports rated Memorial’s Cardiac ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., ... of its strategic partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), ... and effective management of complex spine deformity cases, particularly in children. , GSO’s ...
(Date:4/24/2017)... ORLANDO, FLORIDA (PRWEB) , ... April 24, 2017 ... ... of telehealth technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth ... compliment LG CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed ...
(Date:4/24/2017)... , ... April 24, 2017 , ... The Santana Telehealth ... ATA 2017: Telehealth 2.0 — the American Telemedicine Association’s annual conference, on April 23 ... Project for using telemedicine to improve the lives of the poor and underserved in ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Texas , April 20, 2017  Vivify Health, ... mobile devices, has been awarded a very significant patent ... via EMRs to continual care via digital health.  This ... key intellectual property and further secures Vivify,s position as ... launched in 2009, was the first company to apply ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Company,s consumer product development program, based on ... Society for Investigative Dermatology (SID) 76 th ... and promote the sciences relevant to skin health ...
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
Breaking Medicine Technology: